TR201900057T4 - Selektif histon deasetilaz (HDAC) inhibitörleri olarak yeni azaindol deriveleri ve bunları içeren farmasötik bileşimler. - Google Patents
Selektif histon deasetilaz (HDAC) inhibitörleri olarak yeni azaindol deriveleri ve bunları içeren farmasötik bileşimler. Download PDFInfo
- Publication number
- TR201900057T4 TR201900057T4 TR2019/00057T TR201900057T TR201900057T4 TR 201900057 T4 TR201900057 T4 TR 201900057T4 TR 2019/00057 T TR2019/00057 T TR 2019/00057T TR 201900057 T TR201900057 T TR 201900057T TR 201900057 T4 TR201900057 T4 TR 201900057T4
- Authority
- TR
- Turkey
- Prior art keywords
- pharmaceutical compositions
- new
- azaindole derivatives
- hdac
- histone deacetylase
- Prior art date
Links
- 102000003964 Histone deacetylase Human genes 0.000 title abstract 6
- 108090000353 Histone deacetylase Proteins 0.000 title abstract 6
- 125000005334 azaindolyl group Chemical class N1N=C(C2=CC=CC=C12)* 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20130154455 | 2013-12-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201900057T4 true TR201900057T4 (tr) | 2019-01-21 |
Family
ID=53370682
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2019/00057T TR201900057T4 (tr) | 2013-12-12 | 2014-12-12 | Selektif histon deasetilaz (HDAC) inhibitörleri olarak yeni azaindol deriveleri ve bunları içeren farmasötik bileşimler. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9650379B2 (enExample) |
| EP (1) | EP3080125B1 (enExample) |
| JP (2) | JP2016540024A (enExample) |
| KR (1) | KR101689394B1 (enExample) |
| CN (1) | CN105940001B (enExample) |
| DK (1) | DK3080125T3 (enExample) |
| ES (1) | ES2704704T3 (enExample) |
| HR (1) | HRP20181965T1 (enExample) |
| PL (1) | PL3080125T3 (enExample) |
| PT (1) | PT3080125T (enExample) |
| TR (1) | TR201900057T4 (enExample) |
| WO (1) | WO2015087151A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015157504A1 (en) | 2014-04-11 | 2015-10-15 | Taipei Medical University | Histone deacetylase inhibitors |
| PL3328843T3 (pl) | 2015-07-27 | 2023-02-27 | Chong Kun Dang Pharmaceutical Corp. | Związki będące pochodnymi 1,3,4 oksadiazolosulfonamidów jako inhibitor deacetylazy histonowej 6, oraz kompozycja farmaceutyczna je zawierająca |
| NZ739211A (en) | 2015-07-27 | 2019-05-31 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same |
| RU2695227C9 (ru) * | 2015-07-27 | 2020-03-04 | Чонг Кун Данг Фармасьютикал Корп. | Производные 1,3,4-оксадиазолсульфамида в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция |
| PT3331864T (pt) | 2015-08-04 | 2022-01-18 | Chong Kun Dang Pharmaceutical Corp | Compostos derivados de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica compreendendo os mesmos |
| CA3001666C (en) | 2015-10-12 | 2021-03-30 | Chong Kun Dang Pharmaceutical Corp. | Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
| EP3429591B1 (en) | 2016-03-16 | 2023-03-15 | Kura Oncology, Inc. | Substituted thieno[2,3-d]pyrimidine derivatives as inhibitors of menin-mll and methods of use |
| KR102002581B1 (ko) * | 2016-10-04 | 2019-07-22 | 주식회사 종근당 | 혈액암 치료를 위한 hdac 저해제 및 프로테아좀 억제제 또는 면역조절성 약물을 포함하는 약학적 조합물 |
| WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
| IT201700041723A1 (it) | 2017-04-14 | 2018-10-14 | Italfarmaco Spa | Nuovi inibitori selettivi di HDAC6 |
| TW201920170A (zh) | 2017-09-20 | 2019-06-01 | 美商庫拉腫瘤技術股份有限公司 | 經取代之menin-mll 抑制劑及使用方法 |
| KR102236356B1 (ko) | 2017-11-24 | 2021-04-05 | 주식회사 종근당 | 루푸스의 예방 또는 치료를 위한 조성물 |
| KR102316234B1 (ko) | 2018-07-26 | 2021-10-22 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
| US20220296599A1 (en) * | 2018-10-12 | 2022-09-22 | Chong Kun Dang Pharmaceutical Corp. | Pharmaceutical composition comprising histone deacetylase inhibitor and methotrexate |
| MY207444A (en) | 2019-05-31 | 2025-02-27 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
| BR112021026334A2 (pt) | 2019-06-27 | 2022-05-10 | Medstar Health | Macrófagos ativados por hdac6, composições, e usos dos mesmos |
| WO2021021979A2 (en) | 2019-07-30 | 2021-02-04 | Eikonizo Therapapeutics, Inc. | Hdac6 inhibitors and uses thereof |
| UY38912A (es) * | 2019-10-09 | 2021-05-31 | Biocryst Pharm Inc | Inhibidores del factor d del complemento para administración oral |
| EP4504190A4 (en) | 2022-04-08 | 2026-03-25 | Eikonizo Therapeutics Inc | OXADIAZOLE HDAC6 INHIBITORS AND THEIR USES |
| CN115417877B (zh) * | 2022-09-20 | 2024-05-14 | 杭州师范大学 | 组蛋白去乙酰化酶抑制剂及其制备和在制备抗癌症药物上的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE38506E1 (en) | 1991-10-04 | 2004-04-20 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
| US6174905B1 (en) | 1996-09-30 | 2001-01-16 | Mitsui Chemicals, Inc. | Cell differentiation inducer |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| JP4975941B2 (ja) | 2000-09-29 | 2012-07-11 | トポターゲット ユーケー リミテッド | （ｅ）−ｎ−ヒドロキシ−３−（３−スルファモイル−フェニル）アクリルアミド化合物及びその治療用途 |
| US6897220B2 (en) | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| BRPI0817897A2 (pt) * | 2007-11-02 | 2019-09-24 | Methylgene Inc | composto, composição, e, métodos de inibição da atividade hdac, e de tratamento de uma doença responsiva a um inibidor de atividade hdac |
| JP2011506335A (ja) * | 2007-12-06 | 2011-03-03 | シェーリング コーポレイション | γ−セクレターゼ調節剤 |
| KR101168801B1 (ko) | 2009-03-27 | 2012-07-25 | 주식회사종근당 | 신규한 하이드록사메이트 유도체, 이의 제조방법, 및 이를 함유하는 약제학적 조성물 |
| US8431538B2 (en) | 2009-07-22 | 2013-04-30 | The Board Of Trustees Of The University Of Illinois | HDAC inhibitors and therapeutic methods of using same |
| US9249087B2 (en) * | 2011-02-01 | 2016-02-02 | The Board Of Trustees Of The University Of Illinois | HDAC inhibitors and therapeutic methods using the same |
| CA2840380A1 (en) * | 2011-06-24 | 2012-12-27 | Dana-Farber Cancer Institute, Inc. | Selective inhibitors of histone deacetylase isoform 6 and methods thereof |
| CA2850757A1 (en) | 2011-10-03 | 2013-04-11 | The Trustees Of Columbia University In The City Of New York | Novel molecules that selectively inhibit histone deacetylase 6 relative to histone deacetylase 1 |
| CA2846066A1 (en) * | 2011-10-28 | 2013-05-02 | Chong Kun Dang Pharmaceutical Corp. | Hydroxamate derivatives for hdac inhibitor, and the pharmaceutical composition comprising thereof |
| CN103974956B (zh) | 2011-11-29 | 2016-07-06 | 南京奥昭生物科技有限公司 | 作为hdac6抑制剂和用作抗肿瘤剂的杂环酰胺化合物 |
-
2014
- 2014-12-12 EP EP14869323.7A patent/EP3080125B1/en active Active
- 2014-12-12 PL PL14869323T patent/PL3080125T3/pl unknown
- 2014-12-12 PT PT14869323T patent/PT3080125T/pt unknown
- 2014-12-12 KR KR1020140179702A patent/KR101689394B1/ko not_active Expired - Fee Related
- 2014-12-12 WO PCT/IB2014/002768 patent/WO2015087151A1/en not_active Ceased
- 2014-12-12 DK DK14869323.7T patent/DK3080125T3/en active
- 2014-12-12 US US15/103,597 patent/US9650379B2/en not_active Expired - Fee Related
- 2014-12-12 ES ES14869323T patent/ES2704704T3/es active Active
- 2014-12-12 HR HRP20181965TT patent/HRP20181965T1/hr unknown
- 2014-12-12 CN CN201480073461.XA patent/CN105940001B/zh not_active Expired - Fee Related
- 2014-12-12 TR TR2019/00057T patent/TR201900057T4/tr unknown
- 2014-12-12 JP JP2016539198A patent/JP2016540024A/ja active Pending
-
2018
- 2018-04-12 JP JP2018076529A patent/JP6561167B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018109068A (ja) | 2018-07-12 |
| CN105940001A (zh) | 2016-09-14 |
| ES2704704T3 (es) | 2019-03-19 |
| WO2015087151A1 (en) | 2015-06-18 |
| PT3080125T (pt) | 2018-12-14 |
| US9650379B2 (en) | 2017-05-16 |
| DK3080125T3 (en) | 2019-01-07 |
| CN105940001B (zh) | 2018-02-06 |
| PL3080125T3 (pl) | 2019-06-28 |
| KR101689394B1 (ko) | 2016-12-23 |
| JP2016540024A (ja) | 2016-12-22 |
| EP3080125A4 (en) | 2017-08-02 |
| HRP20181965T1 (hr) | 2019-02-08 |
| JP6561167B2 (ja) | 2019-08-14 |
| US20160289230A1 (en) | 2016-10-06 |
| EP3080125B1 (en) | 2018-10-10 |
| KR20150068923A (ko) | 2015-06-22 |
| EP3080125A1 (en) | 2016-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY184756A (en) | Novel compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same | |
| EA201691516A1 (ru) | Дигидропирролопиридиновые ингибиторы ror-гамма | |
| EA201592068A1 (ru) | Ингибиторы энхансера zeste гомолога 2 | |
| EA201790528A1 (ru) | Дигидропирролопиридиновые ингибиторы ror-гамма | |
| EA201691803A1 (ru) | Ингибиторы калликреина плазмы человека | |
| EA201891191A1 (ru) | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения | |
| EA201690129A1 (ru) | Гетероарильные соединения, пригодные в качестве ингибиторов sumo-активирующего фермента | |
| TR201816176T4 (tr) | Histon deasetilaz 6 inhibitörleri olarak yeni bileşikler ve bunu içeren farmasötik bileşimler. | |
| EA201591296A1 (ru) | Фталазиноны и изохинолиноны в качестве ингибиторов rock | |
| EA201792047A1 (ru) | Новые соединения | |
| TR201904658T4 (tr) | Bisiklik füzyonla birleştirilmiş heteroaril veya aril bileşikleri ve bunların ırak4 inhibitörleri olarak kullanımları. | |
| GEP20217247B (en) | Indole derivatives for use in medicine | |
| MX382991B (es) | Inhibidores de la arginina metiltransferasa y usos de los mismos. | |
| EA201591823A1 (ru) | Ингибиторы ido | |
| EA201490042A1 (ru) | Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak | |
| MX2016014911A (es) | Acidos hidroxamicos heterociclicos como inhibidores de proteina desacetilasa e inhibidores dobles de proteina desacetilasa-proteina cinasa, y metodos de uso de los mismos. | |
| GEP20196942B (en) | Heterocyclic compounds and their use as retinoidrelated orphan receptor (ror) gamma-t inhibitors | |
| EA201790085A1 (ru) | Ингибиторы лизин-специфической деметилазы-1 | |
| MX375219B (es) | Inhibidores de histona demetilasa. | |
| MX382624B (es) | Compuestos farmacéuticos. | |
| EA201500801A1 (ru) | Бензохинолоновые ингибиторы vmat2 | |
| EA201692313A1 (ru) | Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ | |
| EA201691032A1 (ru) | Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ | |
| EA201790519A1 (ru) | Терапевтические соединения в качестве ингибиторов рецептора орексина-1 | |
| EA201791259A1 (ru) | Производные пиперидина в качестве ингибиторов hdac1/2 |